Clinical Trial Update: A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy, safety, and immunogenicity of 9MW0311 in postmenopausal women with osteoporosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• 9MW0311

Snippet

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Conditions: Postmenopausal Women Osteoporosis | Phase 3 | Status: COMPLETED